Brian G Lake Selected Research

Constitutive Androstane Receptor

1/2022	Response to Letter to the Editor from Drs. van Kesteren, Pronk, Heusinkveld, Luijten and Hakkert concerning Yamada et al. (2021): Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR). Crit. Rev. Toxicol. Vol. 51: 373-394.
1/2021	Critical evaluation of the human relevance of the mode of action for rodent liver tumor formation by activators of the constitutive androstane receptor (CAR).
1/2017	Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin.
1/2017	Editor's Highlight: Mode of Action Analysis for Rat Hepatocellular Tumors Produced by the Synthetic Pyrethroid Momfluorothrin: Evidence for Activation of the Constitutive Androstane Receptor and Mitogenicity in Rat Hepatocytes.
6/2015	Mode of action analysis for pesticide-induced rodent liver tumours involving activation of the constitutive androstane receptor: relevance to human cancer risk.
11/2014	Human hepatocytes support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogen sodium phenobarbital in an in vivo study using a chimeric mouse with humanized liver.
4/2009	Comparison of the effects of the synthetic pyrethroid Metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes.
1/2009	Mode-of-action analysis for induction of rat liver tumors by pyrethrins: relevance to human cancer risk.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian G Lake Research Topics

Disease

18	Neoplasms (Cancer) 01/2022 - 07/2002
14	Hypertrophy 05/2024 - 08/2006
5	Adenoma (Adenomas) 01/2022 - 01/2017
4	Liver Cell Adenoma (Hepatocellular Adenoma) 01/2022 - 07/2018
3	Hyperplasia 01/2022 - 01/2017
3	Carcinoma (Carcinomatosis) 01/2021 - 07/2018
1	Body Weight (Weight, Body) 10/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Carcinogenesis 01/2020
1	Hepatomegaly 07/2002

Drug/Important Bio-Agent (IBA)

9	Pyrethrins (Pyrethroids)FDA Link 01/2022 - 08/2006
8	Constitutive Androstane ReceptorIBA 01/2022 - 01/2009
8	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2009
7	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 07/2002
7	EnzymesIBA 02/2019 - 07/2002
6	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 02/2019 - 04/2009
5	Permethrin (Ambush)FDA LinkGeneric 01/2022 - 01/2017
4	XenobioticsIBA 01/2014 - 08/2006
3	PPAR alphaIBA 01/2022 - 01/2019
3	InsecticidesIBA 01/2022 - 01/2019
2	CateninsIBA 10/2020 - 01/2020
2	PesticidesIBA 01/2020 - 06/2015
2	momfluorothrinIBA 01/2017 - 01/2017
2	(2,3,5,6- tetrafluoro- 4- methoxymethylphenyl)methyl- 2,2- dimethyl- 3- (1- propenyl)cyclopropanecarboxylateIBA 01/2017 - 04/2009
1	fluxapyroxadIBA 05/2024
1	MitogensIBA 01/2022
1	glycerol formalIBA 10/2020
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2020
1	Corn Oil (Oil, Corn)IBA 10/2020
1	Piperonyl Butoxide FDA Link 01/2020
1	3-phenoxybenzoic acidIBA 01/2020
1	AcidsIBA 01/2020
1	Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)IBA 01/2020
1	metazachlorIBA 10/2019
1	Pregnenolone Carbonitrile (PCN)IBA 02/2019
1	Cytochrome P-450 CYP3AIBA 02/2019
1	SaltsIBA 07/2018
1	SodiumIBA 07/2018
1	Thyroid HormonesIBA 08/2006
1	Thyroxine (Levothyroxine)FDA LinkGeneric 08/2006
1	Fatty Acids (Saturated Fatty Acids)IBA 07/2002

Therapy/Procedure

1	Withholding Treatment 01/2017